CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 89 enrolled
Drug / intervention
Flortaucipir F18 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04468347
NCT04468347Phase 1Completed
CompareCT.gov

18F-AV-1451 PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease

Avid Radiopharmaceuticals·interventional·Posted Jul 13, 2020·Updated Sep 25, 2020

In Brief

A Phase 1 clinical trial evaluating Flortaucipir F18 and Brain PET scan for Alzheimer Disease and Mild Cognitive Impairment. Completed, enrolled 89 participants.

Detailed Summary

A Phase 1 study designed to evaluate imaging characteristics of flortaucipir in the preclinical, prodromal and dementia phases of Alzheimer's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease, Mild Cognitive Impairment
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 13, 2020
Enrollment StartOct 1, 2014
Primary CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 6.0 years ago

Interventions

Flortaucipir F18drug

IV injection, 240 megabecquerel (MBq) (6.5 mCi)

Brain PET scanprocedure

positron emission tomography (PET) scan of the brain